GPX3 (Glutathione Peroxidase 3)

This integrative single-cell and machine-learning study delineates the molecular heterogeneity of LM in ICC and identifies twelve feature genes linking LM with tumor aggressiveness. These findings provide novel insight into LM-driven oncogenic mechanisms and propose CYC1 and other LM-associated genes as potential biomarkers and therapeutic targets for ICC.

Additionally, jejunal expression of G-protein coupled receptor 41 (GPR41) and Claudin 1 was markedly higher in the weaned piglets of NaB group than those in control group (P < 0.05). Collectively, these findings suggest that NaB supplementation during mid-to-late gestation could improve placental function in sows, which is associated with enhanced antioxidant capacity, attenuated inflammation, and improved intestinal development in the offspring.

The expressions of STAT3, N-cadherin, and CDK2 proteins were down-regulated, and the expressions of GPX3 and TNFSF10B were up-regulated. This study provides a comprehensive understanding of the molecular mechanisms underlying U(VI)-induced pulmonary epithelial cytotoxicity.

These results demonstrate that F-9 cancer cells are significantly more sensitive to SELENOV than normal fibroblasts, with 50 µg/mL sufficient to trigger mitochondrial dysfunction, oxidative stress, and apoptosis. The findings highlight SELENOV's potential as a targeted anticancer agent, particularly for germ cell tumors.

Drug sensitivity analysis (pRRophetic) identified 27 compounds with differential predicted IC50 values between risk groups.Our study demonstrates that macrophage-associated gene signatures are robust predictors of GC prognosis. These findings provide novel insights into immune regulation and potential therapeutic targets in gastric cancer.

This study developed a prognostic model for STAD using the expression levels of MMRGs. Our findings provide insights that could inform future targeted therapeutic approaches.

This study, based on single-cell transcriptome analysis, revealed the potential inhibitory factor GPX3 in metastatic GC and validated its effects on GC growth and metastasis using GC cells and organoids in vitro and in vivo experiments. These findings offer insights into understanding GC heterogeneity and targeting GPX3 in GC therapeutic strategies.

Thirteen genes were associated with DCIS progression, and six genes were validated in the cell experiments. KEGG and GO analyses highlight TME's role in early breast cancer, enhancing understanding of DCIS occurrence and aiding identification of high-risk tumors.

This study provides new experimental evidence supporting GPX3 as a potential therapeutic target for STAD and offers a theoretical foundation for future molecular-targeted therapies for STAD.

This study reveals the signaling pathway mediated by GPX3-TGFB1-ZEB2 and its role in acquired platinum resistance and EMT in TNBC. Our findings suggest that GPX3 is a promising biomarker and potential therapeutic target for the diagnosis, treatment, and prognosis of high-risk TNBC patients.

Moreover, an inverse relationship between OPN3 expression and GPX3 levels was observed, suggesting that OPN3 may drive LUAD progression through the GPX3 pathway. This study offers new insights into the function of OPN3 in LUAD and suggests that targeting the OPN3-GPX3 axis could provide a promising therapeutic strategy for LUAD patients.

The upregulation of WDFY family member 4 (WDFY4), Thrombospondin 1(THBS1), Pentraxin 3 (PTX3), Superoxide dismutase 3 (SOD3) and Glutathione peroxidase 3 (GPX3) genes were confirmed. These insights into the molecular underpinnings of SBIRE offer a novel therapeutic strategy for enhancing tumor suppression and improving clinical outcomes in cancer treatment.